vs
NETSOL TECHNOLOGIES INC（NTWK）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是NETSOL TECHNOLOGIES INC的1.6倍（$30.3M vs $18.8M），NETSOL TECHNOLOGIES INC净利率更高（1.3% vs -221.3%，领先222.7%），REGENXBIO Inc.同比增速更快（43.0% vs 21.1%），NETSOL TECHNOLOGIES INC自由现金流更多（$-5.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 10.3%）
NETSOL科技公司是一家总部位于加利福尼亚州恩西诺的美国软件企业，核心业务为开发汽车租赁领域相关软件产品，为汽车租赁行业提供专业的数字化技术支持。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NTWK vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$18.8M
营收增速更快
RGNX
高出21.9%
21.1%
净利率更高
NTWK
高出222.7%
-221.3%
自由现金流更多
NTWK
多$47.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
10.3%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.8M | $30.3M |
| 净利润 | $246.8K | $-67.1M |
| 毛利率 | 48.0% | — |
| 营业利润率 | 6.9% | -190.0% |
| 净利率 | 1.3% | -221.3% |
| 营收同比 | 21.1% | 43.0% |
| 净利润同比 | 121.5% | -31.2% |
| 每股收益（稀释后） | $0.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NTWKRGNX
| Q4 25 | $18.8M | $30.3M | ||
| Q3 25 | $15.0M | $29.7M | ||
| Q2 25 | $18.4M | $21.4M | ||
| Q1 25 | $17.5M | $89.0M | ||
| Q4 24 | $15.5M | $21.2M | ||
| Q3 24 | $14.6M | $24.2M | ||
| Q2 24 | $16.4M | $22.3M | ||
| Q1 24 | $15.5M | $15.6M |
净利润NTWKRGNX
| Q4 25 | $246.8K | $-67.1M | ||
| Q3 25 | $-2.4M | $-61.9M | ||
| Q2 25 | $2.6M | $-70.9M | ||
| Q1 25 | $1.4M | $6.1M | ||
| Q4 24 | $-1.1M | $-51.2M | ||
| Q3 24 | $70.8K | $-59.6M | ||
| Q2 24 | $-82.9K | $-53.0M | ||
| Q1 24 | $327.5K | $-63.3M |
毛利率NTWKRGNX
| Q4 25 | 48.0% | — | ||
| Q3 25 | 39.4% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 49.8% | — | ||
| Q4 24 | 44.5% | 70.2% | ||
| Q3 24 | 45.0% | 48.8% | ||
| Q2 24 | 51.5% | 52.5% | ||
| Q1 24 | 48.3% | 72.6% |
营业利润率NTWKRGNX
| Q4 25 | 6.9% | -190.0% | ||
| Q3 25 | -12.2% | -176.3% | ||
| Q2 25 | 17.4% | -296.3% | ||
| Q1 25 | 8.9% | 13.6% | ||
| Q4 24 | -3.1% | -242.1% | ||
| Q3 24 | -5.2% | -256.6% | ||
| Q2 24 | 4.9% | -251.3% | ||
| Q1 24 | 8.5% | -408.8% |
净利率NTWKRGNX
| Q4 25 | 1.3% | -221.3% | ||
| Q3 25 | -15.7% | -208.3% | ||
| Q2 25 | 14.0% | -331.8% | ||
| Q1 25 | 8.1% | 6.8% | ||
| Q4 24 | -7.4% | -241.3% | ||
| Q3 24 | 0.5% | -246.3% | ||
| Q2 24 | -0.5% | -237.7% | ||
| Q1 24 | 2.1% | -405.4% |
每股收益（稀释后）NTWKRGNX
| Q4 25 | $0.02 | $-1.30 | ||
| Q3 25 | $-0.20 | $-1.20 | ||
| Q2 25 | $0.22 | $-1.38 | ||
| Q1 25 | $0.12 | $0.12 | ||
| Q4 24 | $-0.10 | $-0.99 | ||
| Q3 24 | $0.01 | $-1.17 | ||
| Q2 24 | $-0.01 | $-1.05 | ||
| Q1 24 | $0.03 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.1M | $230.1M |
| 总债务越低越好 | $337.0K | — |
| 股东权益账面价值 | $35.9M | $102.7M |
| 总资产 | $62.7M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资NTWKRGNX
| Q4 25 | $18.1M | $230.1M | ||
| Q3 25 | $22.7M | $274.2M | ||
| Q2 25 | $17.4M | $323.3M | ||
| Q1 25 | $18.8M | $267.9M | ||
| Q4 24 | $21.3M | $234.7M | ||
| Q3 24 | $24.5M | $255.5M | ||
| Q2 24 | $19.1M | $290.4M | ||
| Q1 24 | $12.3M | $338.7M |
总债务NTWKRGNX
| Q4 25 | $337.0K | — | ||
| Q3 25 | $218.2K | — | ||
| Q2 25 | $134.6K | — | ||
| Q1 25 | $86.8K | — | ||
| Q4 24 | $87.0K | — | ||
| Q3 24 | $92.6K | — | ||
| Q2 24 | $95.8K | — | ||
| Q1 24 | $130.4K | — |
股东权益NTWKRGNX
| Q4 25 | $35.9M | $102.7M | ||
| Q3 25 | $35.8M | $161.5M | ||
| Q2 25 | $37.8M | $213.7M | ||
| Q1 25 | $35.5M | $274.2M | ||
| Q4 24 | $33.9M | $259.7M | ||
| Q3 24 | $34.7M | $301.4M | ||
| Q2 24 | $34.8M | $348.3M | ||
| Q1 24 | $35.3M | $390.7M |
总资产NTWKRGNX
| Q4 25 | $62.7M | $453.0M | ||
| Q3 25 | $62.6M | $525.2M | ||
| Q2 25 | $62.4M | $581.0M | ||
| Q1 25 | $58.1M | $490.9M | ||
| Q4 24 | $59.1M | $466.0M | ||
| Q3 24 | $62.8M | $519.1M | ||
| Q2 24 | $64.2M | $569.4M | ||
| Q1 24 | $63.3M | $629.2M |
负债/权益比NTWKRGNX
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-5.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | -27.2% | -174.0% |
| 资本支出强度资本支出/营收 | 2.0% | 1.7% |
| 现金转化率经营现金流/净利润 | -19.24× | — |
| 过去12个月自由现金流最近4个季度 | $-1.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NTWKRGNX
| Q4 25 | $-4.7M | $-52.3M | ||
| Q3 25 | $5.3M | $-56.0M | ||
| Q2 25 | $441.0K | $-49.3M | ||
| Q1 25 | $-363.4K | $33.6M | ||
| Q4 24 | $-5.1M | $-31.6M | ||
| Q3 24 | $5.5M | $-40.5M | ||
| Q2 24 | $6.5M | $-45.5M | ||
| Q1 24 | $-4.2M | $-55.5M |
自由现金流NTWKRGNX
| Q4 25 | $-5.1M | $-52.8M | ||
| Q3 25 | $4.8M | $-56.5M | ||
| Q2 25 | $-44.1K | $-49.7M | ||
| Q1 25 | $-693.0K | $32.6M | ||
| Q4 24 | $-5.6M | $-32.7M | ||
| Q3 24 | $5.4M | $-40.9M | ||
| Q2 24 | $6.1M | $-46.0M | ||
| Q1 24 | $-4.6M | $-56.0M |
自由现金流率NTWKRGNX
| Q4 25 | -27.2% | -174.0% | ||
| Q3 25 | 32.1% | -189.9% | ||
| Q2 25 | -0.2% | -232.8% | ||
| Q1 25 | -4.0% | 36.6% | ||
| Q4 24 | -36.1% | -154.2% | ||
| Q3 24 | 37.1% | -168.9% | ||
| Q2 24 | 37.0% | -206.2% | ||
| Q1 24 | -29.6% | -358.5% |
资本支出强度NTWKRGNX
| Q4 25 | 2.0% | 1.7% | ||
| Q3 25 | 3.2% | 1.7% | ||
| Q2 25 | 2.6% | 1.8% | ||
| Q1 25 | 1.9% | 1.2% | ||
| Q4 24 | 3.0% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 2.6% | 2.1% | ||
| Q1 24 | 2.4% | 3.6% |
现金转化率NTWKRGNX
| Q4 25 | -19.24× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | -0.26× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 77.94× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -12.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NTWK
| Core Revenue | $18.0M | 96% |
| Other | $816.8K | 4% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
